One Case of Exfoliative Dermatitis Induced by Norvancomycin Hydrochloride for Injection Combined with Imipenem and Cilastatin Sodium for Injection

Abstract

CLC Number:

R994.11

CHEN Furong, CHEN Yanli, DAI Jinzhi, DENG Lili, HU Junfei. One Case of Exfoliative Dermatitis Induced by Norvancomycin Hydrochloride for Injection Combined with Imipenem and Cilastatin Sodium for Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 623-624.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I10/623

References

[1] 刘丽英, 李勇, 古淑仪. 万古霉素致白细胞减少症38例回顾性分析[J]. 中国药物警戒, 2012, 9(2):117-118.
[2] 杨淑桂, 郭冬杰, 周星. 注射用盐酸万古霉素致红人综合征1例[J]. 中国药物警戒, 2011, 8(10):636.
[3] Min Z, Garcia R R, Murillo M, et al.Vancomycin-associated Henoch-Sch nlein purpura[J]. Journal of Infection and Chemoth-erapy, 2017, 23(3): 180-184.
[4] Minhas J S, Wickner P G, Long A A, et al.Immune-mediated reactions to vancomycin: a systematic case review and analysis[J]. Annals of Allergy, Asthma & Immunology, 2016, 116(6): 544-553.
[5] Benoit L, Gray M H, Sligl W I.Severe tremor due to vancomycin therapy: a case report and literature review[J]. International Journal of Infectious Diseases, 2012, 16(8): e636-e637.
[6] 毛璐, 李锦. 去甲万古霉素与万古霉素不良反应分析[J]. 中国医药, 2014, 9(1): 121-123.
[7] 刘杨, 吴菊芳, 萧正伦, 等. 1031例患者应用去甲万古霉素不良反应观察[J]. 中华内科杂志, 2004, 43(11): 815-819.
[8] 张艳, 张运周, 宿英英. 去甲万古霉素致粒细胞缺乏症及红人综合征[J]. 药物不良反应杂志, 2010, 12(4): 290-292.
[9] 李琦恒, 倪鸿昌. 亚胺培南/西司他丁不良反应回顾性调查分析[J]. 中国药物应用与监测, 2010, 7(4):223-225.
[10] 张祥霞, 任丽佳. 注射用亚胺培南西司他丁钠致过敏性休克1例[J]. 中国药物警戒, 2014, 11(1):60.
[11] 徐锦龙, 王雄雄, 陈武, 等. 亚胺培南西司他丁钠致中毒性表皮坏死松解型药疹1例[J]. 中国药物应用与监测, 2014, (5):325-326.
[12] Atanaskovi -Markovi M, Gaeta F, Gavrovi -Jankulovi M, et al.Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins[J]. Journal of Allergy and Clinical Immunology, 2009, 124(1): 167-169.
[13] 刘桦, 张佳丽. 药物过敏反应的免疫学机制研究进展[J]. 中国现代应用药学, 2006, 23(4): 284-286,297.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.